SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-23-024027
Filing Date
2023-07-07
Accepted
2023-07-07 17:08:22
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 312631
2 ex4-9.htm EX-4.9 18236
3 ex31-1.htm EX-31.1 6292
4 ex31-2.htm EX-31.2 6438
  Complete submission text file 0001493152-23-024027.txt   579932

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qlgn-20221231.xsd EX-101.SCH 3292
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qlgn-20221231_lab.xml EX-101.LAB 36257
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qlgn-20221231_pre.xml EX-101.PRE 23752
9 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 6583
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37428 | Film No.: 231077600
SIC: 2834 Pharmaceutical Preparations